Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial Jan 19, 2022
What Health Canada’s New Special Access Program Amendments Mean For Medical Access To Psychedelics Dec 23, 2021
Numinus CEO Payton Nyquvest Says Psychedelic Therapy Shouldn’t Be The ‘Last’ Option For Treatment Nov 21, 2021
